Anti-tumour actions of cannabinoids.

Authors: Burkhard Hinz, Robert Ramer
British Journal of Pharmacology, May 2019

The endocannabinoid system has emerged as an important target for the treatment of many diverse diseases. In addition to the well-established palliative effects of cannabinoids in cancer therapy, phytocannabinoids, synthetic cannabinoid compounds and inhibitors of endocannabin…

Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer.

Authors: Golnaz Sharafi, Hong He, Mehrdad Nikfarjam
Journal of Pancreatic Cancer, 25 January 2019

Background: Cannabinoid extracts may have anticancer properties, which can improve cancer treatment outcomes. The aim of this review is to determine the potentially utility of cannabinoids in the treatment of pancreatic cancer. Methods: A literature review focused on the biolo…

Patient Counseling Guidelines for the Use of Cannabis for the Treatment of Chemotherapy-Induced Nausea/Vomiting and Chronic Pain.

Authors: Patrick Makary, Jayesh R. Parmar, Natalie Mims, Nile M. Khanfar, Robert A. Freeman
Journal of Pain and Palliative Care Pharmacotherapy, December 2018

The use of cannabis medications has grown in recent years for the symptomatic relief of chemotherapy-induced nausea/vomiting (CINV) and chronic pain (cancer-related and non-cancer-related). As states legalize the use of cannabis, it is important for pharmacists and other healt…

Current natural therapies in the treatment against glioblastoma.

Authors: José Ignacio Erices, Ángelo Torres, Ignacio Niechi, Isabel Bernales, Claudia Quezada
Phytotherapy Research, November 2018

Glioblastoma (GBM) is the most common and aggressive brain tumor, which causes the highest number of deaths worldwide. It is a highly vascularized tumor, infiltrative, and its tumorigenic capacity is exacerbated. All these hallmarks are therapeutic targets in GBM treatment, in…

Appraising the “entourage effect”: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.

Authors: Sandra Blasco-Benito, Marta Seijo-Vila, Miriam Caro-Villalobos, Isabel Tundidor, et al
Biochemical Pharmacology, November 2018

Breast cancer is the second leading cause of death among women. Although early diagnosis and development of new treatments have improved their prognosis, many patients present innate or acquired resistance to current therapies. New therapeutic approaches are therefore warrante…

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Authors: Antony J. Mersiades, Annette Tognela, Paul S. Haber, Martin Stockler, Nicholas Lintzeris, et al
BMJ open, 12 September 2018

INTRODUCTION: Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Trials using delta-9-tetrahydrocannabinol-rich (THC) products demonstrate limited antiemetic effect, si…

Dangerous plants in dermatology: Legal and controlled.

Authors: Deeptej Singh, Juliya Fisher, Devorah Shagalov, Aakaash Varma, Daniel M. Siegel
Clinics in Dermatology, May-June 2018

The plant and mushroom kingdoms have species used for intoxication, inebriation, or recreation. Some of these species are toxic. Given that many of these plants or substances are illegal and have histories of abuse, much of the research regarding therapeutic application is bas…

Standardized Cannabis sativa extract attenuates tau and stathmin gene expression in the melanoma cell line.

Authors: Golnaz Vaseghi, Mohamad Javad Taki, Shaghayegh Haghjooy Javanmard
Iranian journal of basic medical sciences, October 2017

OBJECTIVES: Metastasis is the main cause of death in patients with melanoma. Cannabis-based medicines are effective adjunctive drugs in cancer patients. Tau and Stathmin proteins are the key proteins in cancer metastasis. Here we have investigated the effect of a standardized…

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Authors: Susan Short, Christopher Twelves, Lucy Brazil, Catherine McBain, et al
Clinicaltrials.gov, 11 August 2016

An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B). Patient…

Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer.

Authors: Clara Andradas, Sandra Blasco-Benito, Sonia Castillo-Lluva, Patricia Dillenburg-Pilla, et al
Oncotarget, 26 July 2016

The orphan G protein-coupled receptor GPR55 has been directly or indirectly related to basic alterations that drive malignant growth: uncontrolled cancer cell proliferation, sustained angiogenesis, and cancer cell adhesion and migration. However, little is known about the invo…

Using Medical Cannabis in an Oncology Practice

Authors: Donald I. Abrams
Oncology, May 2016

As oncologists, we treat patients who have devastating diagnoses with potent therapies. Hence, we demand solid evidence before recommending any intervention. Unfortunately, when it comes to supporting the use of cannabis in clinical situations, we are frustrated by a dearth of…

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Authors: T. Fisher, H. Golan, G. Schiby, S. PriChen, R. Smoum, I. Moshe, N. Peshes-Yaloz, et al
Current Oncology, March 2016

BACKGROUND: Neuroblastoma (nbl) is one of the most common solid cancers in children. Prognosis in advanced nbl is still poor despite aggressive multimodality therapy. Furthermore, survivors experience severe long-term multi-organ sequelae. Hence, the identification of new ther…